Section of Neurosurgery, Department of Surgery, Aga Khan University, Karachi, Pakistan.
J Pak Med Assoc. 2024 May;74(5):1005-1006. doi: 10.47391/JPMA.24-39.
Assessing treatment efficacy for brain tumours has evolved since its inception with the introduction of MacDonald's criteria, which pioneered the utility of imaging to determine an objective and quantifiable response to treatment. This criterion failed to distinguish pseudo response or progression from progression and did not account for non-enhancing disease therefore; the response assessment in neuro-oncology (RANO) working group was established to account for these limitations. Since, its commencement it has worked to determine response assessment for multiple tumours. As paediatric tumours exhibit heterogeneous and variable-enhancing characteristics, the response assessment in paediatric neuro-oncology (RAPNO) working group was formed to create separate criteria. Six response criteria have been published to date, and the article summarizes them.
评估脑肿瘤的治疗效果自麦克唐纳标准提出以来已经发生了变化,该标准开创了利用影像学来确定治疗的客观和可量化反应的先河。该标准未能区分假性反应或进展与进展,也没有考虑到无强化疾病,因此,神经肿瘤学反应评估 (RANO) 工作组成立以解决这些局限性。自成立以来,它一直在努力确定多种肿瘤的反应评估。由于小儿肿瘤表现出异质性和可变强化的特征,因此成立了小儿神经肿瘤学反应评估 (RAPNO) 工作组来制定单独的标准。迄今为止,已经发布了六个反应标准,本文对其进行了总结。